Characteristics of Australian and New Zealand patients with chronic lymphocytic leukaemia: a lymphoma and related diseases registry report

Martynchyk, A; Wellard, C; Chung, E; Bhopal, SK; McQuilten, ZK; Mulligan, SP; Opat, S; Wood, EM; Hawkes, EA; Anderson, MA

Author(s): Martynchyk, A; Wellard, C; Chung, E; Bhopal, SK; McQuilten, ZK; Mulligan, SP; Opat, S; Wood, EM; Hawkes, EA; Anderson, MA;
Details: Publication Year 2025-06,Volume 55,Issue #6,Page 937-943
Journal Title: Internal Medicine Journal
Abstract: BACKGROUND: Treatment of chronic lymphocytic leukaemia (CLL) has evolved significantly with the advent of targeted agents. Real-world analysis of patients with CLL provides a better understanding of treatment efficacy and toxicity and informs planning of future trials; however, Australasian studies are limited. AIMS: Here we describe the demographics, disease characteristics, treatment and outcome for CLL patients enrolled in the Australia and New Zealand Lymphoma and Related Diseases Registry (LaRDR). METHODS: This study included 365 patients aged >/=18 years with CLL diagnosed between January 2016 and May 2023. RESULTS: Median age at diagnosis was 68 years, with 65% being male. Median follow-up was 15.2 months (range 0-78). 11q, 13q, 17p deletions and trisomy 12 were detected in 12%, 54%, 11% and 14% respectively. During the period of follow-up, 38% of patients commenced first-line therapy. The use of Bruton's Tyrosine Kinase inhibitors and B-cell lymphoma 2 inhibitors increased more than 10-fold following regulatory approval in 2020. Two-year progression-free and overall survival, measured from commencement of first-line therapy, were 67% (95% CI 55-76) and 87% (95% CI 78-93) respectively. CONCLUSION: The increasing use of targeted agents largely reflected availability; however, continuing use of chemoimmunotherapy following regulatory approval of targeted agents was noted in 29% of patients in 2022.
Publisher: Wiley
Keywords: Humans; *Leukemia, Lymphocytic, Chronic, B-Cell/epidemiology/drug; therapy/genetics/diagnosis/therapy/mortality; Male; Aged; Female; *Registries; Australia/epidemiology; New Zealand/epidemiology; Middle Aged; Aged, 80 and over; Adult; Australia and New Zealand; chronic lymphocytic leukaemia; demographics; real world; registry
Research Division(s): Blood Cells And Blood Cancer
PubMed ID: 40116206
Publisher's Version: https://doi.org/10.1111/imj.70037
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2025-04-08 02:51:07

Last Modified: 2025-06-26 09:56:59